First Patient Dosed in NEXUS Phase 2 Trial of Leriglitazone in CALD
News
A Phase 2 trial evaluating leriglitazone, Minoryx Therapeutics‘ investigational oral therapy for boys with cerebral adrenoleukodystrophy (CALD), has dosed its first patient at Hospital Sant Joan de Déu in Spain, the company announced. ... Read more